Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Pediatric Crohn's Disease
NCT05923073Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Mar 2024; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05923073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923073.